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Abstract
Aims/hypothesis The aim of this multicentre, randomised,
controlled crossover study was to determine the efficacy of
adding continuous glucose monitoring (CGM) to insulin
pump therapy (CSII) in type 1 diabetes.
Methods Children and adults (n0153) on CSII with HbA1c
7.5–9.5% (58.5–80.3 mmol/mol) were randomised to (CGM)
a Sensor On or Sensor Off arm for 6 months. After 4 months’
washout, participants crossed over to the other arm for
6 months. Paediatric and adult participants were separately
electronically randomised through the case report form
according to a predefined randomisation sequence in eight
secondary and tertiary centres. The primary outcome was the
difference in HbA1c levels between arms after 6 months.
Results Seventy-seven participants were randomised to the
On/Off sequence and 76 to the Off/On sequence; all were
included in the primary analysis. The mean difference in
HbA1c was –0.43% (–4.74 mmol/mol) in favour of the
Sensor On arm (8.04% [64.34 mmol/mol] vs 8.47%
[69.08 mmol/mol]; 95% CI −0.32%, −0.55% [−3.50,
−6.01 mmol/mol]; p<0.001). Following cessation of glucose
sensing, HbA1c reverted to baseline levels. Less time was
spent with sensor glucose <3.9 mmol/l during the Sensor On
arm than in the Sensor Off arm (19 vs 31 min/day; p00.009).
The mean number of daily boluses increased in the
Sensor On arm (6.8±2.5 vs 5.8±1.9, p<0.0001), together
with the frequency of use of the temporary basal rate (0.75±
1.11 vs 0.26±0.47, p<0.0001) and manual insulin suspend
(0.91±1.25 vs 0.70±0.75, p<0.018) functions. Four vs two
events of severe hypoglycaemia occurred in the Sensor On
and Sensor Off arm, respectively (p00.40).
Conclusions/interpretation Continuous glucose monitoring
was associated with decreased HbA1c levels and time spent
in hypoglycaemia in individuals with type 1 diabetes using
CSII. More frequent self-adjustments of insulin therapy may
have contributed to these effects.
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Introduction
Near normoglycaemia is associated with a reduced risk
of microvascular and macrovascular complications in
type 1 diabetes but is difficult to achieve despite consid-
erable effort from patients and healthcare providers; only
a minority of patients achieve a HbA1c level within the
target range [1–3]. The use of insulin pump therapy
(CSII) reduces the HbA1c level without an increase in
hypoglycaemia, compared with multiple daily insulin
injections in meta-analyses [4, 5], and is recommended
for the improvement of metabolic control [3]. Continuous
glucose monitoring (CGM) has also been associated, in
various randomised controlled trials, with reductions in
HbA1c [6–8] and time spent in hypoglycaemia [9, 10].
Sensor-augmented insulin pump therapy (SAP), combin-
ing CSII and CGM, was recently shown to significantly
decrease HbA1c without an increase in hypoglycaemia in
adults and children, compared with multiple daily injec-
tions, in two large multicentre trials [11, 12]. However,
studies investigating whether SAP can further improve
glycaemic control in patients with type 1 diabetes using
CSII alone have yielded conflicting results [13, 14]. The
present randomised, controlled, crossover study was
therefore designed to determine whether patients with
poorly controlled type 1 diabetes who are already using
insulin pump therapy can achieve improved metabolic
control with the addition of personal CGM, and to eval-
uate associated changes in insulin treatment patterns
while using SAP.
Methods
Study design The study had a multicentre, randomised,
controlled, crossover design.
Participants Participants were recruited at four adult and
four paediatric sites in Europe with experience in the use
of insulin pumps and CGM. Participants were included if
they were aged between 6 and 70 years, had a type 1
diabetes duration of more than 1 year and a HbA1c level
between 7.5% and 9.5% (58.5 and 80.3 mmol/mol). Adult
participants were aged 19−70 years; paediatric participants
were aged 6−18 years. In addition, eligible participants had
been using CSII with rapid-acting insulin analogues for
more than 6 months, were naive to CGM and had success-
fully completed a five-question multiple choice test
concerning pump therapy and general understanding of
diabetes [15]. Exclusion criteria included ≥3 incidents of
severe hypoglycaemia in the last 12 months, a history of
hypoglycaemia unawareness (i.e. hypoglycemia without
symptoms), concomitant chronic disease known to affect
diabetes control and any pharmacological treatment that
might modify glycaemic values.
Randomisation Participants were randomised to either a
Sensor On/Sensor Off (On/Off) or a Sensor Off/Sensor On
(Off/On) treatment sequence, in a 1:1 ratio. Randomisation
was generated electronically through the electronic case
report form according to a predefined randomisation se-
quence (implemented by a statistician). Paediatric and adult
participants were randomised separately. Participants, study
staff and investigators were not blinded to the HbA1c data.
Interventions During a 1-month run-in phase, participants
used a glucometer (Bayer Ascensia Contour; Bayer Diabetes
Care, Basel, Switzerland) and an insulin pump system (Mini-
Med Paradigm REAL-Time System; Medtronic, Tolochenaz,
Switzerland) able to integrate CGM in the study phase. All
participants received structured training on diabetes manage-
ment and device use and had their knowledge assessed, as
previously described [15].
Each treatment period was 6 months long, with a 4-month
washout phase between the two periods. Study visits occurred
every 6 weeks during the treatment periods, when the data
from all devices were uploaded onto a computer system
using diabetes management software (CareLink Therapy
Management System for Diabetes-Clinical; Medtronic,
Tolochenaz, Switzerland). There were no study visits during
the washout period.
All participants wore a continuous glucose monitor
(Guardian REAL-Time Clinical; Medtronic, Tolochenaz,
Switzerland), which they were blinded to (the device screen
was turned off), for 2 weeks prior to randomisation and prior
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to crossover. Participants in the Sensor Off arm wore the
device for 2 weeks prior to each study visit.
No common treatment protocols or fixed algorithms were
provided to the centres [15], and therapy adjustments were
made in consultation with participants at clinic visits. Par-
ticipants were individually encouraged to make self-
adjustments to their treatment using real-time CGM values,
hyper- and hypoglycaemic alerts and trends, or to incorpo-
rate self-monitoring of blood glucose (SMBG) results into
treatment adjustments, with written examples of therapy
changes provided in the optional patient diary. Participants
completed a ten-question test to demonstrate technical
knowledge on the pump (4 weeks before randomisation)
and a 12-question test on CGM (at visit 1 of the On/Off
sequence or visit 6 of the Off/On sequence).
Outcome measure The primary endpoint was the difference
in HbA1c levels between the Sensor On and Sensor Off arms
after 6 months of follow-up, adjusting for baseline levels.
Prespecified secondary endpoints included changes in gly-
caemic patterns, as expressed by mean 24 h glucose and
24 h AUC values, and changes in the time spent in hypo-
glycaemia (<3.9 mmol/l), hyperglycaemia (>10 mmol/l) and
euglycaemia (3.9–10 mmol/l).
Sensor data for the secondary endpoints were extracted
from CareLink Clinical (CareLink Therapy Management
System for Diabetes-Clinical, Medtronic, Tolochenaz,
Switzerland) during the 15-day period prior to the end-of-
period (6-month) visit. For the Sensor On arm, 100% sensor
use was calculated as the number of days in the Sensor On
period multiplied by 288, the maximum number of sensor
readings per day. HbA1c was analysed by a central labora-
tory at screening, randomisation and at 3, 6, 10, 13 and
16 months using a Diabetes Control and Complication
Trial-aligned HPLC method (Laboratorium für Klinische
Forschung, Kiel, Germany).
Data on adverse events were collected at each visit and
the number of SMBG values <3.9 mmol/l were calculated
from the glucose meter downloads for 15 days prior to
the end of each period. Severe hypoglycaemia was de-
fined as an episode requiring assistance from another
person or neurological recovery in response to restoration
of plasma glucose to normal. Ketoacidosis events were
defined as episodes of hyperglycaemia (blood glucose
>13.9 mmol/l) with low serum bicarbonate (<15 mmol/
l), low pH (<7.3) or both, together with either ketonaemia
or ketonuria, that required treatment in a healthcare facil-
ity. Patterns of insulin use (total insulin dose, relative
proportions of basal and bolus doses, number of boluses
and temporary basal rates, and use of basal suspend and
bolus wizard features) during the 15 days prior to the end
of each study period were analysed from the data
uploaded from the insulin pumps.
Sample size A sample size of 124 participants (62 randomised
to sequence On/Off and 62 randomised to sequence Off/On)
provided 90% power to detect a mean difference of 0.3% in the
primary endpoint, assuming an SD of 1.0%, a two-tailed
matched-pairs t test and a type I error of 5%. To account for
the duration of the study and possible dropouts, the sample size
was increased by approximately 20%, to 160 participants.
Analyses The two groups were compared using an ANOVA
with adjustment for period effect and subject as random effect.
Period was included in the model regardless of statistical
significance. The mean difference in HbA1c between the
Sensor On and Sensor Off arms, with the corresponding
95% CI and p value, were estimated. Possible carry-over
effects were minimised in the study design by using a
4-month washout period [15]. The intention-to-treat (ITT)
population consisted of all randomised participants, irrespec-
tive of their compliance with the planned course of treatment
or deviations from the protocol. In the case of missing data,
measurements from the same study period were carried for-
ward to substitute for missing end-of-period values. If no
measurements could be carried forward, the end-of-period
data that were available for only one period were used to
impute missing data in the other period.
Secondary endpoints were compared using an ANOVA
model similar to the one used for the analysis of the primary
endpoint. Analyses were performed in the ITT population. All
statistical analyses were performed using Statistical Analysis
System (SAS), version 9.2 (SAS Institute, Cary, NC, USA),
and p values <0.05 were considered statistically significant.
Ethics The study protocol received institutional or national
Ethics Committee approval at each of the study centres and
the study was conducted in line with the Good Clinical
Practice provisions of the Declaration of Helsinki with all
amendments and local regulatory requirements. Written in-
formed consent or assent was obtained from all participants
before enrolment; parental consent was obtained for partici-
pants aged <18 years.
Results
Recruitment and baseline characteristics Participant dispo-
sition is shown in Fig. 1. From January 2008 to July 2010, a
total of 185 individuals were screened and 153 (52% male)
were randomised after the run-in period; 77 were rando-
mised to the On/Off sequence and 76 to the Off/On se-
quence. A total of 15 participants (10%) dropped out:
eight in the On/Off sequence group and seven in the Off/
On sequence group. All 153 participants were included in
the analysis of the primary endpoint. Six participants were
excluded from secondary analyses owing to absence of
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evaluable sensor data for either treatment sequence. Base-
line characteristics were similar in the two groups (Table 1).
Primary and secondary endpoints After 6 months’ treat-
ment, the mean HbA1c level was 8.04% (64.34 mmol/
mol) in the Sensor On arm and 8.47% (69.08 mmol/mol)
in the Sensor Off arm; the mean difference between arms
was −0.43% (−4.74 mmol/mol) (95% CI −0.32%, −0.55%
[−3.50, −6.01 mmol/mol]; p<0.001). The mean difference
was −0.46% (−5.0 mmol/mol) (95% CI −0.26%, −0.66%
[−2.8, −7.2 mmol/mol]; p<0.001) in paediatric participants
and −0.41% (−4.4 mmol/mol) (95% CI −0.28%, −0.53%
[−3.1, −5.8 mmol/mol]; p<0.001) in adult participants.
The HbA1c level decreased continuously during the
Assessed for eligibility (n=185) 
Excluded (n=32) 
• Did not meet inclusion criteria (n=23) 
• Declined to participate (n=5) 
• Other reasons (n=4)
Primary endpoint analysis (n=153) 
Secondary endpoint analysis (n=147) 
• Excluded from analysis (n=6): no evaluable 
sensor data for either treatment sequence 
Discontinued intervention (n=7) 
• Significant protocol violation (n=2)       
• Device issues, unable to continue (n=5) 
Allocated to OFF/ON sequence (n=76) 
• Received allocated intervention (n=76)
Discontinued intervention (n=8)  
• Significant protocol violation (n=2)       
• Device issues, unable to continue (n=4); personal     
issues (n=2) 
Allocated to ON/OFF sequence (n=77) 






Fig. 1 Participant disposition
Table 1 Baseline characteristics of study participants
Sequence OFF/ON Sequence ON/OFF
Characteristic All participants Adults Children All participants Adults Children
Sample size, n 76 41 35 77 40 37
Mean age (years) 28±17 42±11 12±3.2 28±16 42±10 12±3.6
Male sex, n (%) 37 (49) 20 (49) 17 (49) 42 (54) 18 (45) 24 (65)
Mean weight (kg) 66±21 79±13 52±20 65±23 77±15 53±23
Mean height (cm) 166±17 174±8.8 156±18 165±18 174±10 156±20
BMI (kg/m2) 24±4.5 26±3.2 20±4.0 23±5.0 25±3.3 21±5.4
HbA1c (%) 8.5±0.6 8.4±0.6 8.5±0.6 8.3±0.7 8.1±0.5 8.6±0.7
HbA1c (mmol/mol) 69.4±6.5 68.3±6.5 69.4±6.5 67.2±7.6 65.0±5.5 70.5±7.6
Time since diagnosis of diabetes (years) 14±10 21±8.9 6.3±3.1 16±12 24±11 7.4±4.1
Time since start of CSII (years) 5.1±4.1 6.4±4.8 3.5±2.2 5.0±4.2 6.3±5.3 3.5±1.7
Values are presented as mean±SD, unless stated otherwise. Observed paediatric group (6 to 18 years); observed adult group (21 to 64 years)
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6-month Sensor On arm, and withdrawal of the sensor for
the On/Off sequence resulted in glycaemic control reverting
towards baseline levels during the 4-month washout period
(Fig. 2). The sequence allocation and study periods had no
effect on the primary endpoint in the ANOVA model (p0
0.129 and p00.9503, respectively).
Mean sensor use was 80% (median 84%) of the required
time (mean 81% over the final 4 weeks). In the paediatric
group, mean sensor use was 73% (median 78%) of the
required time (mean 74% over the final 4 weeks); in the
adult group mean sensor use was 86% (median 89%) of the
required time (mean 87% over the final 4 weeks). A total of
72% of participants used the sensor ≥70% of the required
time; 24% (37 participants) >90% of the required time. The
decrease in HbA1c was smaller in the group that used the
sensor <70% of the required time (mean±SD: −0.24±1.11%
[−2.6±12.1 mmol/mol]; p00.03) than in the group that used
it ≥70% of the required time (−0.51±0.07% [−5.6±
0.76 mmol/mol]; p<0.001). An improvement in glycaemic
control was seen across the range of HbA1c levels and age
groups. For participants in the Sensor On period, no signif-
icant correlation was found between the reduction in HbA1c
level and the HbA1c level at baseline (Pearson correlation -
0.056; p<0.507). The centre was significant in the ANOVA
model (p<0.0001); however, it did not modify the effect of
Sensor On vs Sensor Off on HbA1c. The interaction of
centre and treatment was not significant (p00.9306).
Time spent with a sensor glucose level <3.9 mmol/l
was significantly less during the Sensor On period com-
pared with the Sensor Off period (19 vs 31 min/day, respec-
tively; p00.009). In addition, significant differences in the
average daily time spent in euglycaemia (3.9–10 mmol/l)
and hyperglycaemia (>10 mmol/l) were observed in favour
of the Sensor On arm (Table 2). The average daily glucose
level was significantly lower in the Sensor On arm
compared with the Sensor Off arm (8.82 vs 9.44 mmol/l;
p<0.001) and the average daily AUC for glucose levels in
the euglycaemic (3.9−10 mmol/l), hypoglycaemic
(<3.9 mmol/l) and hyperglycaemic (>10 mmol/l) ranges
were significantly lower in the Sensor On group (Table 2).
Participants in the Sensor On arm spent less time than the
Sensor Off arm with glucose levels below 2.8 mmol/l (49 vs
75 min/day, respectively), although this difference was of
borderline significance (p00.065). Glycaemic variability
was significantly lower during the Sensor On period when
calculated as 24 h SD of the mean glucose, but there was no
significant difference when assessed by the mean amplitude of
glycaemic excursions (MAGE) (Table 2). The median number
of finger-stick blood glucose tests performed by the partici-
pants also decreased significantly in the Sensor On arm com-
pared with the Sensor Off arm (4.9 vs 5.5; p<0.001).
Insulin treatment patterns The number of boluses/day was
significantly greater during the Sensor On period than dur-
ing the Sensor Off period (6.8±2.5 vs 5.8±1.9; p<0.0001),
while the daily total insulin dose (49.0±23.4 vs 47.4±22.3
U) or relative proportion of bolus insulin (52.8±10.6% vs
52.5±11.0%) were not significantly different between the
two study periods. In addition, the number of temporary
basal rates per day (0.75±1.11 vs 0.26±0.47; p<0.0001), the
daily use of the manual basal suspend function (0.91±1.25
vs 0.70±0.75; p<0.018) and the bolus wizard calculator
feature (3.82±2.7 vs 3.14±2.5; p<0.0001) were significantly
higher during the Sensor On than during the Sensor Off
period.
Adverse events A total of four severe hypoglycaemic events
(5.70 per 100 patient-years) occurred in the Sensor On arm
and two such events (2.83 per 100 patient-years) occurred in
the Sensor Off arm (p00.40). In addition, there was no
statistical difference in the mean number of point samples
(SMBG) <3.9 mmol/l (On vs Off 7.3±5.5 vs 7.0±5.7; p0
0.62). There was no difference in the rate of diabetic ketoa-
cidosis between the Sensor On and the Sensor Off arms (two
events vs four events; p00.47). A total of 178 non-serious
adverse events were reported during the study periods; 80 in
the Sensor On arm and 98 in the Sensor Off arm.
Discussion
This multicentre, randomised, controlled crossover study
demonstrated a decrease in HbA1c and a concurrent reduction
in time spent in hypoglycaemia, through the addition of CGM
to existing CSII for 6 months in participants with type 1
diabetes. Crossover studies of longer duration are seldom used
in trials evaluating diabetes-related technology. However, bias
resulting from differences in education and patient–healthcare
Fig. 2 Mean (±SEM) HbA1c in participants randomised to Off/On
(solid line) and On/Off (dashed line) sequences (all available observa-
tions): months −1 to 0: run in period; months 1 to 6: first period; months
7 to 10: washout; months 11–16: second period. To convert values for
HbA1c in % into mmol/mol, subtract 2.15 and multiply by 10.929
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provider interactions is largely prevented by this study design.
Moreover, in the present study the number of participants lost
to follow-up was lower than expected and the washout period
prevented any appreciable treatment carry-over.
Although the studies cannot be directly compared, the
significant decreases in HbA1c in both age groups in our study
are not consistent with the results of the Juvenile Diabetes
Research Foundation (JDRF) trial, where no change in meta-
bolic control was demonstrated in children or adolescents
using CGM [7]. Two other randomised controlled trials di-
rectly comparing SAP to CSII alone demonstrated a signifi-
cant improvement in glycaemic control in both the treatment
and control groups, and the observed difference between the
study groups did not attain statistical significance in the ITT
analyses [13, 14]. These substantial study effects, together
with dissimilarities in dropout rates, may account for the
differences between the present study and those in which no
significant improvement in HbA1c was demonstrated. Two
recent meta-analyses of all randomised controlled trials com-
paring CSII with or without CGM also demonstrated a signif-
icant, albeit modest, benefit of CGM [16, 17], with a mean
reduction in HbA1c that was comparable to that found in the
present study. However, unlike the findings in the meta-
analyses, we did not observe any relationship between base-
line HbA1c levels and HbA1c reduction.
Studies consistently show that sufficient sensor use is
crucial to the success of CGM [6, 7, 11, 14]. In the present
study, 72% of participants wore a sensor for more than 70%
of the required time, which is similar to that observed in the
adult cohort, but greater than that in the paediatric cohort, in
the JDRF study [7], and similar to that observed in Sensor-
augmented pump Therapy for A1c Reduction (STAR)3 [11].
The latter study demonstrated that an increase in the fre-
quency of sensor use from 41% to 80% was associated with
a doubling of the HbA1c-lowering effect. Moreover, in the
On/Off sequence there was a loss of effect following the
removal of CGM during the washout period and Sensor Off
arm, whereas no change in the HbA1c was observed during
the washout period in the Off/On sequence. Taken together,
these findings demonstrate that the efficacy of CGM
depends upon its continuous use.
The HbA1c decrease in this study was accompanied by
improvements in several secondary endpoints, including
increased time spent in normoglycaemia, decreased time in
hyperglycaemia and reduced time in hypoglycaemia. A
decrease in time spent in hypoglycaemia in patients with
well-controlled diabetes with substantially lower mean
HbA1c has been previously reported [10]; however, this is
the first report of a concomitant decrease in HbA1c and time
spent in hypoglycaemia in participants with less well
controlled diabetes using CGM.
As participants did not receive specific written instruc-
tions on how to use the data from CGM, it was of interest to
investigate modifications of treatment patterns during the
Sensor On period. More frequent insulin bolus administra-
tion along with more frequent use of temporary basal rates
and manual basal suspend function could contribute to low-
ering HbA1c levels and reducing the time spent in hypogly-
caemia. Indeed, in a large observational study with 1,041
patients on insulin pumps, lower HbA1c was associated with
Table 2 Secondary glycemic endpoints
Variable (n0147a) Sensor Off Sensor On p value
Average daily glucose (mmol/l); median (interquartile range) 9.44 (8.38–10.50) 8.82 (7.94–9.99) <0.001
Average daily min <3.9 mmol/l; median (interquartile range) 31 (10–57) 19 (7.9–38) 0.009
Average daily per cent of glucose readings <3.9 mmol/l;
median (interquartile range)
2.6 (0.90–5.2) 1.7 (0.75–3.4) 0.005
Average daily min spent in euglycaemia (3.9−10.0 mmol/l); mean±SD 669±208 774±232 <0.001
Average daily per cent of glucose readings (3.9–10.0 mmol/l) median;
(interquartile range)
57 (47–68) 65 (53–77) <0.001
Average daily min >10.0 mmol/l; median (interquartile range) 429 (307–568) 348 (227–487) <0.001
Average daily per cent of glucose readings >10.0 mmol/l; median (interquartile range) 38 (27–52) 32 (20–44) <0.001
Average daily AUC <3·9 mmol/l per 24 hb; median (interquartile range) 71 (20–195) 41 (15–113) 0.002
Average daily AUC >10.0 mmol/l per 24 hb; median (interquartile range) 6097 (3,731–9,829) 4039 (2,304–7,665) <0.001
Average daily AUC >13·9 mmol/l per 24 hb; median (interquartile range) 1362 (548–3,242) 722 (210–2,043) <0.001
Average daily AUC <3.9 mmol/l and >10.0 mmol/l per 24 hb; median (interquartile range) 6,240 (3,987–10,158) 4,070 (2,318–7,917) <0.001
24 h SD of glucose values (mmol/l)c 4.29±1.19 3.97±1.12 0.0007
MAGE (mmol/l)b 5.05 4.61 0.6075
a For secondary glycaemic endpoints based on sensor data, the ITT population is 147 as six subjects had no evaluable sensor data for period 1 or
period 2. Summary statistics (mean, SD, median and inter-quartile range) are reported as statistically appropriate
b calculated per 24 h over the number of hours of sensor data available in the 15 days prior to the end of period
c n0143
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more frequent insulin bolus administration [18]. With CGM,
the participants also used the bolus wizard calculator feature
more often. Hence, considered together, our data indicate
that SAP is associated with more active self-adjustments of
the insulin therapy.
The frequency of SMBG values <3.9 mmol/l was not
statistically different between the Sensor On and Sensor Off
arms; however, significantly fewer SMBGs were performed
during the Sensor On arm. The rate of severe hypoglycae-
mia was very low and did not significantly differ between
the Sensor On and Sensor Off arms, however, this study
excluded participants with a known history of severe hypo-
glycaemia. Similarly, the rates of severe hypoglycaemia
were low in the JDRF and STAR3 trials [10, 11], and did
not differ between study groups. None of these trials was
powered to detect differences in severe hypoglycaemia.
Potential limitations apply to this study, which may affect
the generalisability of our findings. The small study effect
observed during the run-in period could have persisted into
the treatment periods. No common protocol was used for
adjusting the therapy based on CGM or SMBG during the
study, which could have lessened the effect of sensor use.
However, a recent study did not show a metabolic benefit of a
physician-led structured use of CGM over patient-led use
[19]. In addition, all participants had pre-existing knowledge
of diabetes management. The definition of hypoglycaemia as
<3.9 mmol/l was conservative. Finally, the decrease in HbA1c
in the Sensor On arm did not plateau after 6 months, as
observed in other trials [7, 11]. Therefore, HbA1c levels may
have continued to decrease following longer treatment. By its
nature, the study precluded blinding. The addition of CGM to
established CSII has cost implications, and analyses are being
conducted to assess the health economic impact on medical
resource utilisation and direct costs.
In conclusion, in both paediatric and adult participants
with type 1 diabetes using CSII therapy alone, the addition
of CGM resulted in an improvement in HbA1c with a con-
comitant decrease in time spent in hypoglycaemia. More
frequent self-adjustments of insulin therapy with SAP may
have contributed to these effects. The removal of CGM
resulted in a loss of metabolic benefit.
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